Archives: Resources
Why “waiting for Phase III” is the most expensive mistake in biotech
Plan early evidence for biotech market access, reimbursement and adoption to reduce Phase III evidence gaps and support long-term value.
Unlocking the power of primary care in chronic disease research
Explore the critical role primary care physicians play in chronic disease management and the value they bring to clinical research.
The 2026 FSP Trends Report
Explore 2026 FSP trends to see how sponsors manage trial complexity, access talent and guide outsourcing decisions.
Metabolic advancing platform
Learn how our metabolic advancing platform can help simplify and strengthen your obesity and metabolic programs.
The Biotech Pulse Report 2026
Explore the 2026 Biotech Pulse survey report to help biotech leaders strengthen clinical development decisions, protect momentum and meet key milestones.
Capital efficiency in cardiovascular outcomes trials
Explore the white paper to learn how integrated CVOT execution can accelerate timelines, manage MACE accrual and improve program value in Phase III trials.
Transforming HEOR with AI and Real-World Data
Explore how AI and real-world data can strengthen HEOR, evidence generation and health economic modeling across the therapy lifecycle.
Accelerated GMP lab support for gene therapy program
Learn how flexible GMP analytical testing helped accelerate gene therapy dose release while supporting faster decisions and quality delivery for patients.
